ÑÎËáÈ¥ÑõÉöÉÏÏÙËØ,phenylephrine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅµçƵÂÊ,discharge frequencyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« èÛéÚËáÅçÍÐάÁÖ,pentoxyverine citrateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËᾫ°±Ëá,arginine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò½Ò©Êг¡,pharmaceutical marketÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ADR,Alternative Dispute ResolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ê¡¼¶,provincial levelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¢ÄªÎ÷ÁÖÄÆ,Amoxicillin sodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ̼Ëáïç,lanthanum carbonateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÉÒÆÂçºÏÎï,Charge-Transfer ComplexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÂé»ÆËØ,ephedrine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·½°±·ÓÍ鰷Ƭ,compound paracetamol and amantadine hydrochloride tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÆÕ³¿¨Òò×¢ÉäÒº,procaine hydrochloride injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »îÐÔ´úлÎï,active metaboliteÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÉúÎï¼ì¶¨·¨,microbiological assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó«¹âÆ«ÕñÃâÒß·ÖÎö,Fluorescence polarization immunoassayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« øÓÕµ¼,enzyme inductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±½»·à­äåï§,bencycloquidium bromideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûËɳÚËØD,Cytochalasin DÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ºÒ©½ð¶î,Consumption sumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹²¡¶¾µ°°×,Antiviral proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¤Ã¸ÒÖÖÆ¼Á,Kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¹Ì弤»î,complement activationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒòÒ©Îï,gene drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©Æ·¹ÜÀí·¨,Drug Administration LawÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÝÊ»ÄÜÁ¦,driving abilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ã׸ñÁÐÄθÆ,Mitiglinide calciumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÂÔØÌå,new carrierÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÈ¸ßÏßͼ,Contour MapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÂÀǶ¾ËØB,neochamaejasmine BÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò°´ó¶¹,Glycine sojaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« רÀû¼ìË÷,patent retrievalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ×֢ʹ,inflammatory painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ÌС°ô×´¸Ë¾ú,Corynebacterium parvumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Õû¸Ä´ëÊ©,rectification measuresÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò»Ëõ¶þÒÒ¶þ´¼,diethylene glycolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Darzens·´Ó¦,Darzens reactionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þ´Îг²¨·¢Éú,Second harmonic generationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¾ÐÔÔ¤²â,toxicity predictionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÒ»ùÊïºì,ethyl eosinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÃÀ½ð¸Õ°·,memantine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨ËáÄÆ,Sodium cholateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Á¦Ñ§Ñо¿,kinetics studyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒõµÀ˨,Vaginal suppositoryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÒÏ©»ùÒÒÃÑ,ethyl vinyl etherÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç·ÖÎö·½·¨,electrochemical determinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¦ÈÜÆ¬,Enteric-coated tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ʽðÖÜת,capital turnoverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÙÈýÔªÏàͼ,pseudo-ternary phase diagramsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¸Àýʽ½Ìѧ,case teachingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×¢ÉäÓðÂɳÀû²¬,oxaliplatin for injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Í»ÊÍ,initial burst releaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë®½â¶¯Á¦Ñ§²ð·Ö,hydrolytic kinetic resolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« άÉúËØEÑÌËáõ¥,vitamin E nicotinateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½á¹¹È·Ö¤,Structural IdentificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÍ·æßËûÃÀõ¥,cefetamet pivoxil hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯Ñ§ºÏ³É·¨,chemical synthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« C18Öù,C18 columnÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏúÊÛÁ¿,sales volumeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁòÇèËáºìÃ¹ËØ,erythromycin thiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Àë×Ó½»»»É«Æ×·¨,ion exchange chromatographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß·Ö×ÓÔÓÖÊ,High molecular weight impuritiesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©·¿ÍйÜ,Pharmacy TrusteeshipÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áöϸ°ûÖê,Tumor cell linesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÃÒ©×Éѯ,medication consultationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« K_(ATP)ͨµÀ,K_(ATP) channelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·½»Ç°·¼×‡fßòƬ,Compound Sulfamethoxazole TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÙÒ©,counterfeit drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·¨Âɹ涨,Legal regulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­°±ËáøÒÖÖÆ¼Á,neuraminidase inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©Æ··çÏÕ¹ÜÀí,drug risk managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËá¶þÑõ±ûàº,dioxopromethazine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÒÀƥ˹͡,Epinastine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Çŵ±´ÌØËá,Fenofibric acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹À£ÑñÒ©,antiulcer drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þ½×µ¼Êý¹âÆ×·¨,Second order derivative spectrophotometryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶îҶǰƤÖÊ,prefrontal cortexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×¢ÉäÓÃÀ¼Ë÷À­ßò,lansoprazole for injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔÉö¶¾ÐÔ,Chronic nephrotoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹ÒҸβ¡¶¾»îÐÔ,Anti-HBV activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȱѪƤ°ê,ischemic skin flapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ßÇßò·¨,carbazole methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö©Öë¶¾ËØ,Spider venomÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×é֯Ũ¶È,Tissue concentrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³õÔÈËÙ·¨,Initial average rate methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×é°·H1Þ׿¹¼Á,Histamine H1 antagonistsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹²¡¶¾»úÖÆ,Antiviral mechanismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐÔÓ¦¼¤,acute stressÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÖÐÔת»¯,chiral inversionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©ÎïתÔ˵°°×,drug transporterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ú¼ÒÒ©ÎïÕþ²ß,national drug policyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÂÈÃ×ÅÁÃ÷,clomipramine hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´«Í³ÊµÑé,traditional experimentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó²¼þÉ豸,hardware equipmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ö¼¶ÓÅ»¯,hierarchy optimizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹úÃñÒâʶ,national consciousnessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·çÏÕ¼à²â,risk monitoringÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±±ÃÀÖÞ,North AmericaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±¡Ä¤·ÖÉ¢·¨,Film dispersion methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©Æ··çÏÕ,drug riskÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«